Rasagiline for the treatment of Parkinson’s disease: an update

Bibliography

• Stocchi F. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson’ disease. Int J Clin Pract 2006;60(2):215-21
   PubMed Web of Science ®Google Scholar
• Finberg JPM, Lamensdorf I, Commissiong JW, Youdim MBH. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm 1996;48(Suppl):95-101
   Google Scholar
• Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-1R(þ)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;132:500-6
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Riederer P, et al. Neuroprotective profile of the multitarget drug resagiline in Parkinson’s disease. Int Rev Neurobiol 2011;100:127-49
   PubMed Web of Science ®Google Scholar
• Gerlach M, Reichmann H, Riederer P. A critical review of evidence for preclinical differences between rasagiline and selegiline. Basal Ganglia 2012;2(Suppl 4):S9-15
   Google Scholar
• MAO-B inhibitors for the treatment of Parkinson’s disease. Mov Disord 2002;17(Suppl 4):S38-44
   PubMedGoogle Scholar
• Goggi J, Theofilopoulos S, Riaz SS, et al. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport 2000;11:3937-41
   PubMed Web of Science ®Google Scholar
• Finberg JPM, Lamensdorf I, Weinstock M, et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999;80:495-9
   PubMedGoogle Scholar
• Kupsch A, Sautter J, Götz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 2001;108:985-1009
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson’s disease. The TEMPO study. Arch Neurol 2002;59:1937-43
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, Feigin PD; for the ADAGIO Study investigators. A double-blind, delayed start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268-78
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additionaltherapies, changes in updrs scores, and non-motor outcomes. Lancet Neurol 2011;10:415-23
   PubMed Web of Science ®Google Scholar
• Jankovic J, Berkovich E, Eyal E, Tolosa E. Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: Post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord 2014;20:640-3
   PubMed Web of Science ®Google Scholar
• Hauser RA, Silver D, Choudhry A, et al. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord 2014;29:1028-34
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks D J, Melamed E, et al. for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-54
   PubMed Web of Science ®Google Scholar
• Parkinson study group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• Elmer L; for the Parkinson Study Group, USA and Canada. Rasagiline is effective and well tolerated in the treatment of Parkinson’s disease (PD) patients with levodopa-related motor fluctuations receiving other adjunctive therapy. Mov Disord 2005;20(10):S138
   Google Scholar
• Elmer LW. Rasagiline adjunct therapy in patients with Parkinson’s disease: Post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 2013;19:930-6
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Z, Chen Y, et al. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson’s disease: a randomized, double blind, parallel-controlled, multi-centre trial. Int J Neuropsychopharmacol 2013;16:1529-37
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 2005;20(2):224-30
   PubMed Web of Science ®Google Scholar
• Rizos A, Martin-Martinez P, Odin P, et al. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson’s disease: an international multicenter study. Parkinsonism Relat Disord 2014;20:1231-5
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. Europ J Neurol 2011;18:1373-8
   PubMed Web of Science ®Google Scholar
• Langston JW, Widner H, Goetz CG, et al. Core assessment program for intra cerebral transplantation CAPIT. Mov Disord 1992;7:2-13
   PubMed Web of Science ®Google Scholar
• Poewe W, Hauser RA, Lang A; ADAGIO Investigators. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Mov Disord 2015;30(4):589-92
   PubMed Web of Science ®Google Scholar
• Smith KM, Eyal E, Weintraub D; for the ADAGIO investigators. Combined rasagiline and antidepressant use in Parkinson’s disease in the ADAGIO study. JAMA Neurol 2015;72:88-95
   Web of Science ®Google Scholar
• Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Beiske AG, Loge JH, Hiermstaad MJ, Svensson E. Fatigue in Parkinson’s disease: prevalence and associated factors. Mov Disord 2010;25:2456-60
   PubMed Web of Science ®Google Scholar
• Friedman JH, Brown RG, Comella C, et al. Fatigue in Parkinons’s disease: a review. Mov Disord 2007;22:297-308
   PubMed Web of Science ®Google Scholar
• Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopa naïve subjects with Parkinson’s disease. Neurology 2008;71:481-5
   PubMed Web of Science ®Google Scholar
• Stocchi F, Abruzzese G, Ceravolo R, Corteklli P, et al. for the FORTE Study Group. Prevalence of fatigue in Parkinson’s disease and its clinical correlates. Neurology 2014;83:215-20
   PubMed Web of Science ®Google Scholar
• Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson’s fatigue scale. Parkinsonism Relat Disord 2005;11:49-55
   PubMed Web of Science ®Google Scholar
• Stocchi F; on behalf of the ADAGIO investigators. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. Europ J Neurol 2014;21:357-60
   PubMed Web of Science ®Google Scholar
• Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord 2002;17:1221-6
   PubMed Web of Science ®Google Scholar
• Woods SP, Troster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J Int Neuropsychol Soc 2003;9:17-24
   PubMed Web of Science ®Google Scholar
• Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011;26(10):1851-8
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson’s disease. Exp Opin Drug Saf 2011;10(4):633-43
   PubMed Web of Science ®Google Scholar
• Solís-García del Pozo J, Mínguez-Mínguez S, de Groot PW, Jordán J. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson’s disease. Expert Opin Drug Saf 2013;12(4):479-86
   PubMed Web of Science ®Google Scholar
• Azilect(R). Package Label. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist
   Google Scholar
• Montgomery EB, Panisset M. Retrospective analysis of the incidence of serotonin toxicity in patients taking rasagiline and antidepressants in clinical trials. Mov Disord 2009;24(S1):359
   Google Scholar
• Ghosh P, Winslow J, Musleh C, et al. The tolerability of rasagiline when used concurrently with serotonin reuptake inhibitors in Parkinson’s disease: a retrospective analysis. Mov Disord 2010;25(Suppl 2):S400
   Google Scholar
• Panisset M, Chen JJ, Rhyee SH, et al. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy 2014;34(12):1250-8
   PubMed Web of Science ®Google Scholar
• Reyes D, Kurako K, Galvez-Jimenez N. Rasagiline induced hypersexuality in Parkinson’s disease. J Clin Neurosc 2014;21(3):507-8
   PubMed Web of Science ®Google Scholar
• Vitale C, Santangelo G, Erro R, et al. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson’s disease: Report of 2 cases. Parkinsonism Relat Disord 2013;4(19):483-4
   Web of Science ®Google Scholar